BioLife Solutions, Inc. (BLFS)
| Market Cap | 1.89B +48.2% |
| Revenue (ttm) | 106.69M +30.1% |
| Net Income | 57.98M |
| EPS | 1.16 |
| Shares Out | 48.91M |
| PE Ratio | 33.19 |
| Forward PE | 134.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,445,978 |
| Open | 37.16 |
| Previous Close | 37.30 |
| Day's Range | 36.95 - 38.83 |
| 52-Week Range | 17.86 - 39.76 |
| Beta | 1.82 |
| Analysts | Hold |
| Price Target | 31.29 (-18.96%) |
| Est. Earnings | Nov 5, 2026 |
About BLFS
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduc... [Read more]
Financial Performance
In 2025, BioLife Solutions's revenue was $96.21 million, an increase of 28.89% compared to the previous year's $74.65 million. Losses were -$4.60 million, -77.23% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for BLFS stock is "Hold." The 12-month stock price target is $31.29, which is a decrease of -18.96% from the latest price.
News
BioLife Solutions Transcript: EGM 2026
Stockholders approved the merger agreement with Repligen, along with the advisory compensation and adjournment proposals. The two-step transaction would leave the surviving entity as a direct wholly-owned Repligen subsidiary.
BioLife Solutions Proxy statement: Proxy filing
BioLife Solutions filed a proxy statement on September 30, 2026, providing details for shareholder voting and corporate governance matters.
BioLife Solutions Proxy statement: Proxy filing
BioLife Solutions filed a proxy statement on September 9, 2026, providing details for shareholder voting and corporate governance matters.
BioLife Solutions Proxy statement: Proxy filing
BioLife Solutions filed a proxy statement on September 4, 2026, providing details for shareholder voting and corporate governance matters.
BioLife Solutions Reports Second Quarter 2026 Financial Results
Total revenue of $28.5 million, up 21% over Q2 2025 GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65% GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income ta...
BioLife Solutions Earnings release: Q2 2026
BioLife Solutions released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
BioLife Solutions Quarterly report: Q2 2026
BioLife Solutions has published its Q2 2026 quarterly earnings report on August 6, 2026.
BioLife Solutions to be acquired by Repligen in $1.5B cell therapy deal
BioLife Solutions, a Bothell, Wash.-based company developing tools for cell and gene therapy, is being acquired for $1.5 billion by the life sciences corporation Repligen.
Repligen to buy cell therapy maker BioLife in $1.5 billion deal
Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at about $1.5 billion, to expand the drugmaking equipment provider's presence in the fast-growing ce...
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
Fast-tracks Repligen's leadership and customer solution offering in high-growth cell therapy market by adding BioLife's differentiated, high-margin recurring revenue business
BioLife Solutions Slides: Investor presentation
BioLife Solutions has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
BioLife Solutions Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose 25% year-over-year to $27.5M, led by BPM demand, with adjusted EBITDA up 15%. Guidance for 2026 revenue of $112.5–$115M and margin expansion was reaffirmed, as operational improvements and new product launches are expected to drive growth.
BioLife Solutions Earnings release: Q1 2026
BioLife Solutions released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
BioLife Solutions Quarterly report: Q1 2026
BioLife Solutions has published its Q1 2026 quarterly earnings report on May 7, 2026.
BioLife Solutions Reports First Quarter 2026 Financial Results
Total revenue of $27.5 million, up 25% over Q1 2025 GAAP gross margin and non-GAAP adjusted gross margin of 64% GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of r...
BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
BOTHELL, Wash., April 23, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") mar...
BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
Award Recognizes Technologies That Address Important Industry Needs and Advance Prior Standards BOTHELL, Wash., April 21, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading develop...
BioLife Solutions Slides: Investor presentation
BioLife Solutions has posted slides in relation to its latest quarterly earnings report, which was published on February 27, 2026.
BioLife Solutions Earnings Call Transcript: Q4 2025
Delivered 29% revenue growth and margin expansion in 2025, driven by commercial BPM customers and portfolio optimization. 2026 guidance calls for 17–20% revenue growth, positive GAAP net income, and continued margin improvement, with growth led by commercial demand.
BioLife Solutions Annual report: Q4 2025
BioLife Solutions has published its Q4 2025 annual report on February 26, 2026.
BioLife Solutions Earnings release: Q4 2025
BioLife Solutions released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations
Fourth quarter 2025 revenue from continuing operations of $24.8 million, up 20% year-over-year; Full year 2025 revenue of $96.2 million, up 29% year-over-year GAAP gross margin of 63% and non-GAAP ad...
BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026
BOTHELL, Wash., Feb. 17, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") mark...
BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market
BOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, a...
BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2025 Unaudited Revenue from Continuing Operations
Fourth quarter unaudited revenue from continuing operations of $24.8 million increased 20% from the prior year fourth quarter Full year unaudited revenue from continuing operations of $96.2 million ex...